HemaSphere (Jun 2022)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  • D. Beauvais,
  • M. Sourisseau,
  • H. Béhal,
  • S. Alfandari,
  • N. Simon,
  • E. Faure,
  • I. Yakoub-Agha

DOI
https://doi.org/10.1097/01.HS9.0000848160.85133.ee
Journal volume & issue
Vol. 6
pp. 1209 – 1210

Abstract

Read online

No abstracts available.